Close Menu

NEW YORK (GenomeWeb) – EntroGen said today that it has received CE-IVD marking for its BRCA Complete kit for exome sequencing of the BRCA1 and BRCA2 genes.

The test is a targeted next-generation sequencing assay for use on Illumina's MiniSeq, MiSeq, and NextSeq platforms. It can detect somatic mutations in BRCA1 and BRCA2 with limit of detection of roughly 2 percent and uniformity and average sequencing coverage of 95 percent and 0.2X, respectively, the company said.

The kit also comes with data interpretation software for reporting clinically relevant mutations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
15
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing. 

May
16
Sponsored by
PerkinElmer

This webinar will discuss a comprehensive end-to-end workflow for soil metagenomic shotgun sequencing that offers an unbiased alternative to amplicon-based approaches to assess the composition of culture-free microbial communities and predict functional profiles.